Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of MHT is associated with superior weight loss outcomes.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. ・Tumor size closely matched body weight and fat levels, suggesting fat ...